<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pmed</journal-id><journal-id journal-id-type="flc">plme</journal-id><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0030511</article-id><article-id pub-id-type="publisher-id">06-PLME-C-0832</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correspondence</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Cell Biology</subject>
          <subject>Immunology</subject>
          <subject>Biochemistry/Drug Discovery</subject>
          <subject>Immunology/Allergy and Hypersensitivity</subject>
          <subject>Rheumatology</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>Autoimmune diseases</subject>
          <subject>Drugs and adverse drug reactions</subject>
          <subject>Pain</subject>
          <subject>Rheumatoid arthritis</subject>
          <subject>Rheumatology</subject>
        </subj-group>
      </article-categories><title-group><article-title>Spinal Delivery of p38: TNF-alpha Inhibitors</article-title><alt-title alt-title-type="running-head">Correspondence</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Tobinick</surname>
            <given-names>Edward</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1">
        <label>1</label>
        <addr-line>Institute for Neurological Research, Los Angeles, California, United States of America</addr-line>
      </aff><author-notes>
        <corresp id="cor1">* <email xlink:type="simple">etmd@ucla.edu</email></corresp>
      <fn fn-type="conflict" id="n2">
        <p> The author has pending and issued US and international patents, including US patents 6,015,557; 6,982,089; and others, which describe methods of perispinal administration of etanercept. The author also owns stock in Amgen.</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>11</month>
        <year>2006</year>
      </pub-date><pub-date pub-type="epub">
        <day>28</day>
        <month>11</month>
        <year>2006</year>
      </pub-date><volume>3</volume><issue>11</issue><elocation-id>e511</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2006</copyright-year><copyright-holder>Edward Tobinick</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article page="e338" related-article-type="companion" vol="3" xlink:href="info:doi/10.1371/journal.pmed.0030338" xlink:title="Research Article" xlink:type="simple">
				<article-title>Regulation of Peripheral Inflammation by Spinal p38 MAP Kinase in Rats </article-title>
			</related-article><funding-group><funding-statement>The author received no specific funding for this article.</funding-statement></funding-group><counts>
        <page-count count="1"/>
      </counts><!--===== Restructure custom-meta-wrap to custom-meta-group =====--><custom-meta-group>
        <custom-meta>
          <meta-name>citation</meta-name>
          <meta-value>Tobinick E (2006) Spinal delivery of p38: TNF-alpha inhibitors. PLoS Med 3(11): e511. doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0030511" xlink:type="simple">10.1371/journal.pmed.0030511</ext-link></meta-value>
        </custom-meta>
      </custom-meta-group></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title/>
      <p>The new study by Boyle and colleagues provides important data on basic science mechanisms involved in pain and inflammation [<xref ref-type="bibr" rid="pmed-0030511-b001">1</xref>]. Their data, along with that from previous studies, provides further basic scientific evidence documenting p38–TNF-alpha interactions, and suggests that spinal p38 or spinal TNF-alpha blockade may have clinical relevance [<xref ref-type="bibr" rid="pmed-0030511-b001">1</xref>,<xref ref-type="bibr" rid="pmed-0030511-b002">2</xref>]. The present study documents that p38 activation may be occurring predominantly in microglia. The present study, therefore, joins other recent work which suggests the importance of p38-glial-TNF-alpha interactions in neuroinflammation and synaptic signaling [<xref ref-type="bibr" rid="pmed-0030511-b003">3–6</xref>]. This increasing evidence may have clinical relevance not only to arthritis pain, but also to the pathogenesis of various forms of neuropathic pain and Alzheimer disease [<xref ref-type="bibr" rid="pmed-0030511-b001">1–8</xref>].</p>
      <p>Because the present study suggests that spinal delivery may be more effective than systemic delivery when attempting to intervene in spinally-mediated inflammatory mechanisms, the authors note the potential importance of developing compounds that may bypass the blood-brain barrier. The present author speculates that the rapid and significant clinical effects noted following perispinal administration of etanercept in small pilot studies suggest that perispinal administration of p38 inhibitors may also allow these compounds to reach the spinal cord and dorsal root ganglia in therapeutically effective amounts [<xref ref-type="bibr" rid="pmed-0030511-b007">7</xref>,<xref ref-type="bibr" rid="pmed-0030511-b008">8</xref>]. It is hypothesized that this may be possible via passage through the vertebral portion of the cerebrospinal venous system, and this may explain the efficacy of perispinal etanercept in the above cited studies [<xref ref-type="bibr" rid="pmed-0030511-b007">7–9</xref>]. Previous studies have documented that epidural administration of large molecules may result in delivery to the endoneurial space [<xref ref-type="bibr" rid="pmed-0030511-b010">10</xref>]. This evidence, along with the basic scientific evidence provided by the present study of the potential clinical importance of spinal delivery, supports consideration of investigation of this novel route of administration.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="pmed-0030511-b001">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Boyle</surname><given-names>DL</given-names></name><name name-style="western"><surname>Jones</surname><given-names>TL</given-names></name><name name-style="western"><surname>Hammaker</surname><given-names>D</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>CI</given-names></name><name name-style="western"><surname>Rosengren</surname><given-names>S</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Regulation of peripheral inflammation by spinal p38 MAP kinase in rats.</article-title>
					<source>PLoS Med</source>
					<volume>3</volume>
					<fpage>e338</fpage>
					<comment>doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0030338" xlink:type="simple">10.1371/journal.pmed.0030338</ext-link></comment>
				</element-citation>
      </ref>
      <ref id="pmed-0030511-b002">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Schafers</surname><given-names>M</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>CI</given-names></name><name name-style="western"><surname>Sommer</surname><given-names>C</given-names></name><name name-style="western"><surname>Sorkin</surname><given-names>LS</given-names></name></person-group>
					<year>2003</year>
					<article-title>Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons.</article-title>
					<source>J Neurosci</source>
					<volume>23</volume>
					<fpage>2517</fpage>
					<lpage>2521</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0030511-b003">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Culbert</surname><given-names>AA</given-names></name><name name-style="western"><surname>Skaper</surname><given-names>SD</given-names></name><name name-style="western"><surname>Howlett</surname><given-names>DR</given-names></name><name name-style="western"><surname>Evans</surname><given-names>NA</given-names></name><name name-style="western"><surname>Facci</surname><given-names>L</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity: Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease.</article-title>
					<source>J Biol Chem</source>
					<volume>281</volume>
					<fpage>23658</fpage>
					<lpage>23667</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0030511-b004">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Takeuchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Kawanokuchi</surname><given-names>J</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner.</article-title>
					<source>J Biol Chem</source>
					<volume>281</volume>
					<fpage>21362</fpage>
					<lpage>21368</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0030511-b005">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Stellwagen</surname><given-names>D</given-names></name><name name-style="western"><surname>Malenka</surname><given-names>RC</given-names></name></person-group>
					<year>2006</year>
					<article-title>Synaptic scaling mediated by glial TNF-alpha.</article-title>
					<source>Nature</source>
					<volume>440</volume>
					<fpage>1054</fpage>
					<lpage>1059</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0030511-b006">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Sommer</surname><given-names>C</given-names></name><name name-style="western"><surname>Schafers</surname><given-names>M</given-names></name><name name-style="western"><surname>Marziniak</surname><given-names>M</given-names></name><name name-style="western"><surname>Toyka</surname><given-names>KV</given-names></name></person-group>
					<year>2001</year>
					<article-title>Etanercept reduces hyperalgesia in experimental painful neuropathy.</article-title>
					<source>J Peripher Nerv Syst</source>
					<volume>6</volume>
					<fpage>67</fpage>
					<lpage>72</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0030511-b007">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Tobinick</surname><given-names>E</given-names></name><name name-style="western"><surname>Gross</surname><given-names>H</given-names></name><name name-style="western"><surname>Weinberger</surname><given-names>A</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>H</given-names></name></person-group>
					<year>2006</year>
					<article-title>TNF-alpha modulation for treatment of Alzheimer's disease: A 6-month pilot study.</article-title>
					<source>MedGenMed</source>
					<volume>8</volume>
					<fpage>25</fpage>
				</element-citation>
      </ref>
      <ref id="pmed-0030511-b008">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Tobinick</surname><given-names>EL</given-names></name><name name-style="western"><surname>Britschgi-Davoodifar</surname><given-names>S</given-names></name></person-group>
					<year>2003</year>
					<article-title>Perispinal TNF-alpha inhibition for discogenic pain.</article-title>
					<source>Swiss Med Wkly</source>
					<volume>133</volume>
					<fpage>170</fpage>
					<lpage>177</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0030511-b009">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Tobinick</surname><given-names>E</given-names></name></person-group>
					<year>2006</year>
					<article-title>The cerebrospinal venous system: Anatomy, physiology, and clinical implications.</article-title>
					<source>MedGenMed</source>
					<volume>8</volume>
					<fpage>53</fpage>
				</element-citation>
      </ref>
      <ref id="pmed-0030511-b010">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Byrod</surname><given-names>G</given-names></name><name name-style="western"><surname>Rydevik</surname><given-names>B</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>BR</given-names></name><name name-style="western"><surname>Olmarker</surname><given-names>K</given-names></name></person-group>
					<year>2000</year>
					<article-title>Transport of epidurally applied horseradish peroxidase to the endoneurial space of dorsal root ganglia: A light and electron microscopic study.</article-title>
					<source>J Peripher Nerv Syst</source>
					<volume>5</volume>
					<fpage>218</fpage>
					<lpage>226</lpage>
				</element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>